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ABSTRACT 
 The importance of gut microbiota in gastrointestinal (GI) physiology was well described, 
but our ability to study gut microbial ecosystems in their entirety was limited by culture-based 
methods prior to the sequencing revolution. The advent of high-throughput sequencing opened 
new avenues, allowing us to study gut microbial communities as an aggregate, independent of 
our ability to culture individual microbes. Early studies focused on association of changes in gut 
microbiota with different disease states which was necessary to identify a potential role for 
microbes and generate novel hypotheses. Over the past few years the field has moved beyond 
associations to better understand the mechanistic implications of the microbiome in the 
pathophysiology of complex diseases. This movement also has resulted in a shift in our focus 
towards therapeutic strategies which rely on better understanding the mediators of gut 
microbiota-host crosstalk. It is not surprising the gut microbiome has been implicated in 
pathogenesis of functional gastrointestinal disorders (FGIDs) given its role in modulating 
physiological processes such as immune development, GI motility and secretion, epithelial 
barrier integrity, and brain-gut communication. In this review, we focus on the current state of 
knowledge and future directions in microbiome research as it pertains to FGIDs. We summarize 
the factors which help shape the gut microbiome in humans. We discuss data from animal 
models and human studies to highlight existing paradigms regarding the mechanisms underlying 
microbiota-mediated alterations in physiological processes and their relevance in human 
interventions. While translation of microbiome science is still in its infancy, the outlook is 
optimistic and we are advancing in the right direction towards precise mechanism based 
microbiota therapies.   
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INTRODUCTION 
The human gut is home to a complex microbial ecosystem with bacteria, fungi, viruses, 
and archaea which exist in a mutualistic relationship with the host in homeostatic conditions. The 
microbial members along with their genetic content are often referred to as the gut microbiome 
and can be viewed as a “dynamic organ” capable of mediating a wide variety of biochemical 
transformations that directly impact host physiology in health and disease1, 2. However, a 
disruption in this equilibrium can lead to alteration of host physiology resulting in disease states 
such as functional gastrointestinal disorders (FGIDs).   
The role for gut bacteria in FGIDs such as irritable bowel syndrome (IBS) has been well 
described. An estimated 10% of IBS cases begin after an episode of infectious gastroenteritis3. 
However, the study of intestinal microbial ecosystems was limited by our inability to identify 
bacteria without cultivating them in the laboratory. At the turn of the century, ground-breaking 
advances in the genomics era and sequencing technologies4, 5 gave way to culture-independent 
molecular approaches allowing us to not only identify and characterize microbial communities 
based on similarities in DNA sequences, but also provide knowledge that has significantly 
improved our ability culture bacteria that were previously considered unculturable6. 
These advances have led to extensive characterization of microbial communities in 
FGIDs over the past decade. While no consistent “microbial signature” has been associated with 
FGIDs, several lines of evidence support a role for gut microbes in the development of FGID 
symptoms7. There has been a significant effort to move beyond describing associations between 
the gut microbiome and FGIDs to defining mechanisms underlying microbial contributions to the 
pathophysiology of FGIDs.  
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 In this review, as a part of our effort to define a path from bench to bedside, we will 
summarize factors affecting the gut microbiome and describe a conceptual framework for the 
role of the gut microbiome in FGIDs. This foundation will allow us to identify gaps in our 
current body of knowledge and develop strategies to translate microbiome science into improved 
diagnosis, prognosis, and management of FGIDs. 
Factors that shape the gut microbiota 
 Gut microbial composition and diversity is largely the consequence of host selection 
pressures such as genetics, habits, sex, and location within the gastrointestinal (GI) tract as well 
as environmental factors including diet (Figure 1). Gut microbial diversity varies with age, and 
substantial differences are seen at the extremes of life8. At birth, assembly of the gut microbiota 
begins with colonization from environmental microbes (e.g., maternal vaginal, fecal, skin 
microbiota). In the subsequent months to years, gut microbial communities continue to shift in 
response to key life events (e.g., exposure to solid foods, illnesses, antibiotics) with gradual 
increases in diversity and convergence to an “adult-like” microbiota9-11. The adult gut microbiota 
is relatively stable over time and surprisingly resilient to temporary perturbations, changing as 
we get older to a distinct and less diverse microbiome12. 
Sex associations (Figure 1) with the gut microbiota have been characterized by increased 
relative abundance of Firmicutes and lower Bacteroidetes in women compared to men and may 
be further influenced by body mass index13, 14. Host genetic influence15,16,17 18, 19,20  on the gut 
microbiome is apparent from studies of monozygotic and dizygotic twin pairs that demonstrate 
shared community structures between related individuals21 and temporally stable heritable taxa17. 
However,  the effect size is likely small given recent microbial-genetic association studies 
showing environmental factors to have substantially greater impact on the gut microbiome than 
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genetics22. The impact of both short23 and long term dietary patterns24 on the gut microbiome 
cannot be overstated25, 26. The role of diet27 in microbial alterations is of significant interest in 
FGIDs as dietary intolerances are commonly reported in FGIDs and patients may alter or restrict 
their diets based on perceived associations between symptoms and food28, 29. The interaction of 
diet, gut microbiome, and symptoms in FGIDs (reviewed in 30) has not been well studied and the 
long term consequences of current dietary interventions with reported benefit in IBS, such as 
supplementation with psyllium fiber and the low FODMAP (fermentable oligosaccharides, 
disaccharides, monosaccharides, and polyols) diet31, 32, on the gut microbiome remain to be seen. 
Other modifying factors (Figure 1) include psychological stress33,34, physical activity35, 
tobacco use36, alcohol consumption37, and antibiotic exposure38, 39,40. In one population-level 
analysis of gut microbiome variation, 69 factors were shown to correlate with microbiome 
community variation, with stool consistency emerging as the most influential covariate 41.   
The distribution and composition of the gut microbiota changes along the length of the GI 
tract (Figure 2) and across the lumen, mucus layer, and the epithelium42, 43. Bacterial density 
increases from more proximal to distal sites44. Microbial abundance and community structure in 
the proximal intestine is affected by gastric acid, pancreaticobiliary secretions, and fast transit45. 
Spatial niche partitioning of microbial populations can also be a result of mucus from goblet 
cells 46 and differential oxygen tolerance47. Together, these factors lead to distinct 
microenvironments driving the biogeographical stratification of microbes across the GI tract.  
EFFECT OF THE GUT MICROBIOTA ON HOST PHYSIOLOGY  
Gut microbiota and gastrointestinal motility 
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Altered GI motility and transit have long been recognized in the pathobiology of FGIDs 
such as IBS48 and functional dyspepsia (FD)49, 50. GI motility and the gut microbiota have 
reciprocal effects (reviewed in 1), highlighting a bidirectional relationship (Figure 3). Gut 
microbes can accelerate GI transit51, 52. In turn, accelerated GI transit can alter the composition 
and spatial organization of microbial communities by creating luminal conditions suited for the 
growth of specific bacterial taxa or by affecting bacterial adherence1. Interestingly, GI motility 
related changes in the gut microbiome can further perpetuate the alteration in GI motility as a 
positive feedback effect53. Several microbial mediators (Table 1) of GI motility have been 
identified (Figure 3), including short chain fatty acids (SCFAs) and bile acids. SCFAs are 
produced by fermentation of dietary starches or complex carbohydrates by gut bacteria54, while 
bile acid deconjugation and dehydroxylation by gut bacteria regulates the quantity and 
derivatives of bile acids in the colon. SCFAs and bile acids may affect gut motility (Table 1). 
Prokinetic effects of bile acids can be mediated by the G protein-coupled bile acid receptor 
TGR5 (or GPBAR1), expressed by enteric neurons and enteroendocrine cells based on findings 
from animal models55. Interestingly, microbial mediators of GI motility can vary by diet56, 57. For 
example, turmeric, a commonly used spice in Asian dishes, stimulates gallbladder contraction 
and increases intraluminal bile acids through its active ingredient, curcumin. Similarly, SCFA 
concentrations can vary based on dietary carbohydrate and protein intake. Other microbial 
products or metabolites (Table 1) that have been identified as potentially relevant in microbial 
regulation of GI motility include: bacterial lipopolysaccharide, which can improve survival of 
enteric neurons by activation of toll-like receptor 4 (TLR4)58. Preliminary studies support the 
roles of other microbial metabolites such as hydrogen sulfide59,60, tryptamine61, and hydrogen 
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gas62 in regulation of human GI motility by their putative effects on GI smooth muscle and the 
enteric nervous system1.  
Gut microbiota and gastrointestinal sensation 
Abdominal pain in IBS48 and other FGIDs63 such as FD64 and functional abdominal 
bloating/distention65 has been attributed to visceral hypersensitivity to mechanical and chemical 
stimuli. Evidence for a role of the gut microbiome in regulating GI sensation (Figure 3) comes 
from gnotobiotic studies showing transfer of the visceral hypersensitivity phenotype following 
transplantation of gut microbiota from patients with IBS into germ-free (GF) mice 66. A recent 
study by Riba et al.67 demonstrated a correlation between visceral hypersensitivity and increase 
of Escherichia coli abundance followed by induction of hypersensitivity in response to E. coli 
gavage in mice. Disruption of the gut microbiota in early-life also has been associated with long-
term changes in visceral sensitivity, emphasizing the importance of the gut microbiome in 
neurodevelopment of pain pathways68. The exact mechanisms by which bacteria affect visceral 
perception and sensation still need to be determined. A few putative mechanisms include: 
microbial induction of epithelial µ-opioid and cannabinoid receptors as shown with oral 
administration of Lactobacillus strains in rodents69; regulation of central70 and peripheral 
neuronal pathways71; anti-nociceptive effects from inhibition of transient receptor potential 
vanilloid as shown with administration of Lactobacillus reuteri72 in rats; microbial metabolites 
(e.g., organic acids) or byproducts (e.g. nitric oxide)73 altering sensation; and microbially-derived 
bioactive molecules such as γ-aminobutyric acid (GABA) as shown with administration of 
GABA-producing Bifidobacterium dentium74. The translation of findings from animal models to 
humans can, however, be challenging. For instance, rectal administration of butyrate increases 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
CGH_Microbiome_FGID_8 
 
colonic hypersensitivity in rats75, but results in decreased visceral sensitivity in healthy 
humans76. Hence, findings from animal studies, while valuable, need to be validated in humans.  
Gut microbiota and intestinal permeability 
 The intestinal epithelium and the overlaying mucus layer serve a key role in protecting 
the host by providing a physical and immunological barrier against potentially harmful 
pathogens while also regulating fluid and nutrient absorption77. Increased permeability or 
disruption of the epithelial barrier has been implicated in the pathophysiology of FGIDs78, 79. 
Microbes (Figure 3) can directly alter expression of tight junction proteins such as claudin-380 
and zonula occludens-181 or enhance expression of genes involved in tight junction signaling82. 
Microbial metabolites such as bile acids83,84 and SCFAs can also regulate intestinal permeability 
(Table 1). The mucus layer overlaying the epithelium is a reservoir of antimicrobial peptides and 
immunoglobulins and provides the first line of defense against gut bacteria85. The mucus layer is 
compositionally rich in polysaccharides which can serve as a nutrient source for subsets of 
bacteria. Hence microbial starvation such as with decreased consumption of fiber can increase 
microbial reliance on the mucus polysaccharides resulting in degradation of the mucus layer and 
increasing susceptibility to opportunistic pathogens and inflammation27, 86. 
Gut microbiota, immune activation, and inflammation 
 Inflammation or immune activation involving both the innate and adaptive immune 
systems has been described in subsets of patients with FGIDs87,88. There are several lines of 
evidence in support of the activation of mucosal and systemic immune responses by gut 
microbiota (Figure 3). Post-infectious FD is associated with increased numbers of duodenal 
CD68+ cells and eosinophils when compared with other subtypes of FD (epigastric pain 
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syndrome, post-prandial distress syndrome), and healthy states89. Increased expression of pro-
inflammatory cytokines may be elicited through interactions between bacterial components and 
pattern recognition receptors including TLRs such as TLR2 and TLR4 that have been associated 
with IBS90. The gut microbiota can also influence immune activation via effects on lineage 
differentiation of T-cell subsets91, host-receptor mediated signaling as seen with L. reuteri 
activation of histamine H2 receptor signaling92, and production of microbial metabolites (Table 
1).  
Gut microbiota and intestinal secretion 
 Changes in small intestinal93 and colonic secretion represents another pathophysiologic 
disturbance in FGIDs that may be influenced by the gut microbiome48 (Figure 3). Secretory 
mechanisms are common therapeutic targets94, 95 of medications used to treat FGIDs. Microbial 
mediators of altered intestinal secretion96 include metabolites from breakdown of dietary 
polysaccharides as well as bile acids (Table 1). Specific bile acids, such as deoxycholate and 
chenodeoxycholate, can stimulate intestinal chloride secretion97, 98 which is accompanied by 
water. SCFAs, like bile acids, are important intraluminal determinants of mucus and water 
secretion through effects on sodium and water influx99, duodenal bicarbonate secretion100, and 
colonic epithelial 5-HT3 receptor expression101.  
Gut microbiota and gastric function 
 Disturbances in gastric motor and sensory function, including impaired gastric 
accommodation and increased intragastric pressure, may underlie FGIDs and are often related to 
food intake102.  There is a paucity of data in support of microbial regulation of gastric function. 
The administration of the prebiotic arabinoxylooligosaccharide in healthy volunteers was not 
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associated with changes in gastric sensitivity, compliance, or accommodation despite increased 
colonic fermentation102. Reported associations between the presence of small intestinal bacterial 
overgrowth (SIBO) and delayed gastric emptying103 have not discerned whether associations are 
a result of microbial mechanisms or merely representative of underlying impairment in small 
intestinal motility and other confounding factors including chronic acid suppression and opioid 
analgesics104. Recent evidence showing a similar gastric emptying time among patients with and 
without SIBO suggests that bacterial overgrowth does not necessarily predispose to impaired 
gastric emptying105, 106.  
Gut microbiota and central nervous system function 
 The bidirectional microbiome-gut-brain axis (Figure 3) represents the reciprocal 
regulation of the gut microbiome and the central nervous system (CNS). Recent studies highlight 
the role of the gut microbiome in modulating brain-gut communication, which may significantly 
affect the pathophysiology of symptoms associated with FGIDs107,108. Signals from the CNS can 
influence GI physiology while simultaneously shaping the gut microbial fingerprint as seen in 
early life stress rodent models which exhibit alterations in gut microbial community 
composition109. Similar findings have been described in other rodent stress models33. Conversely, 
microbial colonization and community composition are critical to development of the 
hypothalamus–pituitary–adrenal axis as evidenced by the exaggerated adrenocorticotropic 
hormone and corticosterone release in germ-free (GF) mice. This exaggeration is attenuated 
following colonization with Bifidobacterium infantis110. A different strain within the same genus, 
Bifidobacterium longum NCC3001, decreases anxiety-like behavior in mice through vagally 
mediated pathways111. Microbial metabolites such as SCFAs and microbially-derived 
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neurotransmitters such as GABA and 5-HT may further impact brain function and mental 
health108.  
FUNCTIONAL GI DISORDERS  
Role of gut microbiota in pathophysiology of irritable bowel syndrome 
The gut microbiota of patients with IBS is an area of considerable interest, and has been 
the most extensively studied among the various FGIDs (reviewed in 44). Despite the lack of a 
uniform “IBS-microbiota” pattern, key observations include a decrease in α-diversity and 
alterations in relative abundance of specific taxonomic groups including an increased ratio of 
Firmicutes to Bacteroidetes, decreased Lactobacillus and Bifidobacterium, and increased 
Streptococcus and Ruminococcus spp.112. Cross-sectional analysis of extensively phenotyped 
cohorts also has revealed that while stool consistency is a significant contributor to gut 
microbiome compositional variation, the contribution imparted by IBS was much less41. These 
data highlight the importance of investigating specific pathophysiologic disturbances, beyond 
merely providing descriptive analyses of a heterogeneous patient populations in elucidating the 
role of the gut microbiome in IBS. Correlative associations between the gut microbiome and IBS 
have been followed by efforts to better characterize the mechanistic link between the 
microbiome and pathophysiology of symptoms associated with IBS (Table 2). Among the 
various aforementioned aspects of gut physiology that are affected by the gut microbiome, many 
are directly implicated in the pathophysiology of IBS.  
Summary of findings from animal studies 
Animal models, although imperfect correlates to IBS pathophysiology in humans, have 
allowed us to explore putative interactions between the gut microbiome and mechanisms 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
CGH_Microbiome_FGID_12 
 
implicated in IBS such as altered motility, visceral hypersensitivity, increased permeability, 
immune activation, intestinal secretion, and disturbances in central mechanisms. De Palma et 
al.52 recently demonstrated that GF mice colonized with the fecal microbiota of diarrhea-
predominant IBS (IBS-D) patients exhibited faster GI transit, increased colonic permeability, 
increased anxiety-like behavior, and increased infiltration by CD3+ T lymphocytes compared to 
those colonized by microbiota from healthy controls. Study of specific IBS pathways include 
reports describing microbiota-induced hypersensitivity to colonic distension in GF rats 
inoculated with the fecal microbiota from IBS patients66. Microbial regulation of host immune 
responses may be further relevant to IBS. An increase in mucosal immune cells including mast 
cells, macrophages or monocytes, T-cells, and eosinophils has been reported in both pediatric 
and adult FGID populations79, 113, 114. Mast cells contain biologically active substances including 
histamine, tryptase, cytokines, and membrane-derived arachidonic acid metabolites (e.g., 
prostaglandins) that are released upon their activation. These mediators may alter nociceptive 
pathways in IBS115 or increase intestinal permeability116. Macrophages and monocytes are 
important in modulating the adaptive immune responses and producing proinflammatory 
cytokines such as IL-6 and IL-8 which in some studies are increased in IBS patients117. The role 
of gut microbes in these immune pathways remains unknown.   
Summary of findings from studies in adult IBS patients 
 Numerous studies have examined microbiome-related effects on pathophysiological 
changes in IBS, building upon work performed in animal models. Interventional studies 
investigating the use of probiotic and antibiotic therapy in IBS have led to identification of 
potential microbial effects on transit (Table 2). Treatment with a probiotic containing 
Bifidobacterium lactis118 accelerates whole gut transit and improves symptoms in patients with 
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constipation-predominant IBS (IBS-C), while treatment with the non-absorbable antibiotic 
rifaximin is associated with increases in both ascending colonic emptying and overall colonic 
transit rate at 48 hours119 in non-constipated IBS patients. A role for the gut microbiome in 
immune modulation was suggested by findings from the clinical trial wherein B. infantis 35624 
alleviated symptoms and was associated with normalization of abnormal IL-10/IL-12 ratios in 
IBS patients120. Colonic mucosal gene expression profiling of IBS patients also has found 
differential expression of genes associated with host immune responses against microbial 
invasion, further suggesting that immune activation may be shaped by microbial interactions121. 
Alterations in mucus-associated bacteria that may influence mucus integrity and intestinal 
secretion (e.g. Akkermansia muciniphila, Ruminococcus gnavus and Ruminococcus torques) also 
have been associated with IBS122. Microbially-mediated effects on intestinal secretion in IBS 
may be a consequence of differential bile acid biotransformation by the gut microbiome96. This 
concept is supported by the decreased concentrations of fecal unconjugated bile acids known to 
stimulate colonic secretion (deoxycholate and chenodeoxycholate) in IBS-C123. Regarding the 
role of the microbiome-gut-brain axis in IBS (reviewed in 124 and 125), probiotic therapy has been 
shown to modulate CNS function in healthy volunteers126 through effects on brain regions 
controlling processing of emotion and sensation. More recently, in a recent placebo controlled 
trial in IBS patients, treatment with the probiotic B. longum NCC3001 was associated with 
improved symptoms of depression and changes in brain activation patterns measured by 
functional magnetic resonance imaging127.  
Summary of findings from studies in pediatric IBS patients  
 Similar to adult studies, the composition of the gut microbiome differs between children 
with IBS and age-matched healthy controls, despite lack of a uniform “IBS-microbiota” 
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signature across studies. One study enrolling children ages 7-12 years found pediatric IBS to be 
associated with decreased relative abundance of Bacteroides spp. and increased relative 
abundance of the class Gammaproteobacteria, including Haemophilus parainfluenzae, along 
with increased abundance of novel taxa related to the genus Ruminococcus. In this cohort, 
microbiota composition correlated with abdominal pain severity and frequency, and could be 
used to distinguish IBS-C from unsubtyped IBS128. Another study of children ages 11-18 years 
found IBS-D to be associated with increased abundance of the genera Veillonella, Prevotella, 
Lactobacillus, and Parasporobacterium, and with decreased abundance of Bifidobacterium and 
Verrucomicrobium129. By adding fecal metabolomic profiling to microbiome signatures, stool 
from children with IBS-D could be more accurately discriminated from that of healthy controls, 
with formate, pyruvate, and glucose being the most predictive metabolites130. Fecal microbial 
community composition also might be used to predict which children with IBS are more likely to 
respond to a low-FODMAP diet: in two separate studies, responders had distinct baseline 
microbiome signatures compared to non-responders131, 132.  
Among the most studied probiotics in pediatric IBS is Lactobacillus rhamnosus GG, 
which was found in a meta-analysis of three randomized, placebo-controlled trials (RCTs) to 
confer a modest but significantly increased rate of treatment response versus placebo133. Two 
multicenter, randomized, double-blind, placebo-controlled crossover studies provide further 
evidence of microbiota involvement in pediatric IBS. One study found that VSL#3 improved GI 
symptoms134, while the other reported that a combination of three bifidobacteria resolved 
abdominal pain and improved quality of life to a greater extent than placebo135. On the other 
hand, psyllium fiber reduced pain episodes in an RCT enrolling children with IBS without 
altering the composition of the gut microbiota based on 16S ribosomal RNA analysis136.  
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RCTs in children with functional abdominal pain (FAP) have revealed that L. reuteri 
DSM 17938 is effective in treating abdominal symptoms. Jadrešin et al.137 demonstrated a 
reduction in days with pain and pain severity in children with IBS and FAP.  In studies focused 
specifically on FAP, Romano et al.138 reported reduced pain severity and Weizman et al.139 and 
Maragkoudaki et al.140 both reported reduced pain severity and frequency in those treated with 
the probiotic compared with placebo. 
In summary, both animal and human studies underscore the importance of the gut 
microbiome in mediating peripheral and central mechanisms implicated in IBS. Moreover, 
factors affecting gut microbiota composition are akin to the etiological factors in IBS and 
probiotic interventions have a generally beneficial effect. However, given the heterogenous 
nature of the disease with multiple putative mechanisms, our broad nontargeted approach 
without consideration for the underlying physiological disturbance likely dilutes the overall 
impact and makes it difficult to ascertain the precise benefit of microbiota modulation. As we 
move forward, it will be important to phenotype patients based on the underlying physiological 
alterations so that we can develop targeted approaches directed towards specific microbes 
driving the host phenotype.  
Role of gut microbiota in pathophysiology of functional dyspepsia 
 Similar to IBS, multiple pathogenic mechanisms including altered gastric function, 
visceral hypersensitivity, low grade inflammation or immune activation, increased duodenal 
permeability, and abnormal CNS function have been postulated to contribute to symptoms in 
FD141. As summarized above, gut microbiota have been shown to modulate the majority of these 
physiological functions. Although data on the gastroduodenal microbiome and its particular role 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
CGH_Microbiome_FGID_16 
 
in FD are sparse, there are a few studies that lay the groundwork for future work investigating 
the role of microbial community alterations in FD.  
Summary of findings from animal studies 
In general, animal studies investigating microbial effects on putative pathophysiologic 
mechanisms in FD are lacking given the absence of reliable models. The described effects are 
attributed to fermentative end products such as SCFAs. Bacterially-derived or ingested SCFAs 
can alter duodenal bicarbonate secretion100. In addition, the absorption of SCFAs can also 
influence the luminal bacterial population which may be relevant in FD100.  
Summary of findings from studies in adult patients with functional dyspepsia 
There are few human studies describing the gut microbiome in patients with FD, hence 
the precise role of the microbiota remains unknown. SIBO has been proposed to trigger 
symptoms in FD142, although studies examining the role of SIBO in FD are limited by the 
relative inaccessibility of the more distal regions of the small intestine and concerns regarding 
accuracy and interpretation of available testing methods for the diagnosis of SIBO143. Recently, 
Zhong et al.144 found the relative abundance of the anaerobic genera Prevotella, Veillonella and 
Actinomyces were significantly decreased in the duodenal mucosa of nine patients with FD 
compared to controls. Interestingly, severity of symptom responses to a standardized meal was 
positively correlated with mucosal bacterial load, which in turn was inversely correlated with 
bacterial diversity. Igarashi et al145 found that gastric fluid samples from patients with FD were 
characterized by an increased Bacteroidetes to Proteobacteria ratio and absence of Acidobacteria. 
In contrast, healthy volunteers had a decreased Bacteroidetes to Proteobacteria ratio and presence 
of Acidobacteria. Non-blinded probiotic therapy with Lactobacillus gasseri OLL2716 was 
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subsequently associated with shifts in gastric fluid microbial community composition similar to 
that found in healthy controls. In another RCT among patients with FD, rifaximin treatment was 
associated with significant improvement in global dyspeptic symptoms, belching, and post-
prandial fullness/bloating, further suggesting a potential role for the microbiome in FD146.  
Summary of findings from studies in pediatric patients with functional dyspepsia 
 Relatively little is known regarding the gut microbiome in pediatric FD. Although the 
previously highlighted multicenter, randomized, double blind, placebo controlled crossover study 
reported that a combination of three probiotic bifidobacteria improved pain scores and quality of 
life among 48 children with IBS, no benefit was observed among the 25 enrolled children who 
had FD, perhaps owing to the small number of patients treated135. Likewise, the moderate overall 
benefit associated with L. rhamnosus GG treatment in an RCT of children with IBS or FD was 
not observed in the subset of children with FD147. However, it would be premature to make 
definitive conclusions given the small sample size (n=20 with FD versus n=37 with IBS). 
 In summary, the gut microbiome can affect mechanisms underlying FD similar to IBS, 
but the microbial community composition of the stomach and small bowel remain elusive and 
much work is needed before we can target specific microbial mediators that drive symptoms in 
FD. The overall positive impact of probiotics is encouraging and highlights the need for better 
mechanistic understanding in order to develop more precise microbiota-based therapeutics.   
Role of gut microbiota in pathophysiology of functional abdominal bloating 
 Abdominal bloating and distension are common complaints among patients suffering 
from FGIDs, and are among the most challenging symptoms to treat. The pathophysiologic 
mechanisms contributing to bloating are poorly understood, although SIBO and alterations in gut 
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microbial communities have been hypothesized148 to play a role through microbial fermentation 
of dietary nutrients. As this is predominantly a subjective sensation, there are no animal models 
to mimic these symptoms.  
Summary of findings from adult patients with functional abdominal bloating 
The majority of clinical studies investigating symptoms of bloating have been performed 
in IBS patients, with bloating and distension evaluated as secondary endpoints148. A recent study 
showed depletion of operational taxonomic units within Subdoligranulum and Anaerovorax, 
belonging to the families Ruminococcaceae and Eubacteriaceae, respectively, in IBS patients 
without bloating compared to those with bloating and to healthy controls149. Placebo-controlled 
studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant 
reduction in bloating scores with rifaximin compared to placebo150-152. Efficacy of probiotic 
administration for symptoms of bloating have been less consistently reported153 although some 
studies in IBS patients have suggested benefit with specific probiotic strains including B. lactis 
DN-173118, Bifidobacterium animalis DN-173 010154, and VSL#3155. 
Summary of findings from pediatric studies 
 Little is known regarding the microbiome in functional abdominal bloating in children. 
The trial noted previously by Weizman and colleagues139, which reported benefit for abdominal 
pain with the probiotic L. reuteri DSM 17938, also reported a lower incidence of perceived 
abdominal distention and bloating. Similarly, patients in the VSL#3 trial had decreased 
abdominal bloating/gassiness compared to placebo134.  
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 In summary, while gut microbes can potentially impact these symptoms both via 
fermentative end products and by their effect on visceral sensation, we need to better 
characterize the potential microbial mediators in order to develop relevant therapeutics.   
Role of gut microbiota in pathophysiology of functional constipation  
 There is evidence supporting an association between the altered mucosal and fecal 
microbiota and chronic constipation156, 157. Most of our knowledge regarding the effects of the 
gut microbiota on peripheral mechanisms associated with constipation, such as GI motility, 
comes from animal studies. However, in recent years, several studies have been published 
exploring the gut microbiome in patients with constipation (Table 2).  
Summary of findings from animal studies 
Investigation of the causal relationship between alterations in gut microbial communities 
and constipation has been described in a recent study158 reporting upregulation of 5-HT 
transporter and decreased 5-HT content in the colonic tissue of germ-free mice that received 
fecal microbiota from constipated patients. 5-HT was negatively correlated with transit time and 
changes were accompanied by decreased relative abundance of the phylum Firmicutes and 
increased Bacteroidetes in mice receiving fecal microbiota from constipated patients. Genus 
level analyses further showed decreased relative abundance of Clostridium, Lactobacillus, 
Desulfovibrio and Methylobacterium and increased relative abundance of Bacteroides and 
Akkermansia. The findings suggest a potential role for gut microbiota in the pathogenesis of 
chronic constipation via increased expression of 5-HT transporter158. Interestingly, gut 
microbiota changes resulting from constipation can further impact GI motility, suggesting a more 
complex interaction with feedforward regulation rather than a simple cause-effect relationship53. 
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The potential role of microbially-derived metabolites is further supported by findings of delayed 
GI transit and altered SCFA and bile acid profiles following transfer of fecal microbiota from 
patients with slow transit constipation to antibiotic-treated mice159. 
Summary of findings from adult patients with functional constipation 
Several studies have reported a positive relationship between prolonged colon transit 
times, with increased richness and diversity of the fecal microbiome in adults without prior 
history of GI disorders160,161. However, the association between constipation and the gut 
microbiome may involve mechanisms beyond that of slow transit. In a study of adults with 
chronic constipation, overall composition of the colonic mucosa-associated microbiota could 
discriminate patients with constipation from control subjects independent of transit time157. 
Taxonomic profiling of the fecal microbiome from patients with functional constipation (FC) and 
healthy volunteers has shown decreased abundance of Bacteroides, Roseburia, and Coprococcus 
in FC patients. Furthermore, healthy volunteers were found to have a gut microbiome enriched in 
genes involved in carbohydrate, fatty acid, and lipid metabolism while FC patients harbored a 
high abundance of genes involved in methanogenic pathways, hydrogen production, and 
glycerol162. Analysis of functional gene targets in constipated and healthy females also has 
demonstrated increased abundance of hydrogenogenic (hydrogen producing) and 
hydrogenotrophic (hydrogen utilizing) genes by qPCR in colonic mucosa of constipated 
individuals163.  
Summary of findings from pediatric studies  
 In a cross-sectional study of 8 constipated obese children and 14 non-constipated obese 
children, FC was associated with decreased abundance of the phylum Bacteroidetes, including a 
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significant reduction of the genus Prevotella, and increased abundance of multiple genera within 
the phylum Firmicutes, including Blautia, Coprococcus, and Ruminococcus164. A recent 
systematic review included seven RCTs enrolling a total of 515 children that investigated the 
effects of probiotics in pediatric FC. Although two of the included studies, those evaluating L. 
reuteri DSM 17938165 and B. longum166, reported significantly increased defecation frequency in 
the treatment arm, the meta-analysis concluded that there is currently insufficient evidence to 
support the use of probiotics for pediatric FC167. Finally, although a low-fiber diet is a known 
risk factor for FC in children168, there is currently little evidence to support the use of fiber for 
pediatric FC. Multiple systematic reviews note the sparse data and high risk of bias among the 
current evidence base169-172.  
 In summary, the reciprocal interactions between GI transit and gut microbiota suggest 
that even if changes in gut microbiota are initiated by a change in transit, the altered microbial 
community can perpetuate the alteration in GI transit, highlighting the adaptability of the gut 
microbial community. Consequently, we need to think beyond the simple cause-effect paradigm 
as irrespective of the inciting event that alters the microbial community, these changes can still 
perpetuate a disease phenotype. The effect of gut microbiota on the host serotonergic system 
provides a plausible target for altering GI transit.  
Role of gut microbiota in pathophysiology of infant colic  
Infant colic, a characteristic group of behaviors featuring prolonged crying, is present in 
up to 25% of infants at 6 weeks of life173 and is associated with increased risk of recurrent 
abdominal pain and allergic disorders later in childhood174. Underlying mechanisms are unclear, 
due in part to a lack of small animal models. Multiple pathophysiologies, including gut 
microbiome alterations, have been proposed to promote abdominal pain. Early culture-dependent 
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studies by Savino et al. revealed that colicky infants were more frequently colonized by 
anaerobic gram-negative proinflammatory bacteria and less frequently colonized by lactobacilli 
when compared to non-colicky infants175, 176. Subsequent molecular studies confirmed 
enrichment of proinflammatory and gas producing taxa within Proteobacteria in stool from 
colicky infants177-179.  
Given these observations, the probiotic L. reuteri, one of the few endogenous lactobacilli 
in the human GI tract, was proposed as a means of normalizing these gut microbial community 
alterations and potentially reducing crying times in infant colic and has become the most 
extensively studied microbiome-targeting therapy for colic. L. reuteri has been tested in six 
prospective, RCTs: two meta-analyses that included more than 400 infants found that L. reuteri 
significantly reduced crying time in formula fed infants by a mean of nearly one hour per day180, 
181
. Of note, the only other therapy to demonstrate efficacy in infant colic was fennel oil while 
often-recommended interventions including simethicone and maternal diet manipulation 
produced mixed results181. Interestingly, L. reuteri also has shown benefit in prevention trials, 
reducing the risk of developing colic at three months of life182, 183. Finally, a number of small 
studies have tested other microbiome-targeting therapies, including L. rhamnosus GG184, 185 and 
a synbiotic combination of fructooligosaccharide and seven probiotics186; these small studies 
generated mixed results. 
Modulating the gut microbiota for treatment of functional gastrointestinal disorders 
Targeting the gut microbiota for therapeutic intervention in FGIDs remains an area of 
significant interest for patients and clinicians. Probiotics have been studied extensively in adult 
and pediatric FGID populations as previously discussed and summarized in Table 2. A prior 
systematic review of probiotics in IBS suggested evidence for efficacy on global IBS symptoms, 
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abdominal pain, bloating, and flatulence187; however, there remain many unanswered questions 
regarding strain-specific effects, mechanisms of action, mode of administration and dosing, and 
patient selection. Despite their relative accessibility and general safety, clinical recommendations 
regarding specific probiotic use in FGIDs are limited by a lack of rigorous clinical trial data. 
Rifaximin has been studied in functional dyspepsia146, abdominal bloating, and flatulence150, and 
is approved for treatment of adults with IBS-D151. The exact mechanisms by which rifaximin 
exerts its effects in IBS, however, remain uncertain, with a recent study of patients with non-
constipated IBS showing borderline effects on microbial richness and increased rates of proximal 
colonic emptying but no clear effects on bowel function, permeability, or production of 
intraluminal metabolites119. More recently, results of several trials investigating the efficacy of 
fecal microbiota transplantation (FMT) for IBS have been reported. In one RCT among patients 
with moderate-to-severe IBS, higher response (p=0.049) rates at three months, defined as a 75-
point improvement in the IBS severity scoring system, were observed in patients receiving FMT 
(65%) compared to those receiving placebo (43%). However, differences were no longer 
significant at 12 months followup188. On the other hand, a separate multicenter RCT189 
comparing FMT capsules to placebo in patients with diarrhea-predominant IBS was unable to 
demonstrate significant symptom relief at three months with FMT, although subgroup analysis 
suggested patients with post-infectious IBS experienced greater improvement with FMT 
compared to placebo (p=0.09). The role of FMT in IBS needs to be better defined as there may 
be specific features in the donor microbiome as well as additional recipient characteristics that 
predict clinical outcomes. FMT, however, represents a stop-gap measure and it is imperative that 
we determine which specific microbes, microbial consortia, or microbial products yield benefit 
in FGIDs to provide precision care without unwanted effects.  
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TRANSLATING MICROBIOME RESEARCH: Where are we, and what do we need? 
 The role of the gut microbiome in FGIDs must be considered in the context of the 
environment, the host, and host-specific factors. In order for us to advance the field and develop 
novel microbiota-based diagnostic and therapeutic targets in FGIDs, we will need to move from 
simple taxonomic associations to functional phenotypes and mechanism-based studies. In animal 
studies, we need to determine the specific microbes or microbial products as well as the 
mechanisms that alter host physiology. The use of gnotobiotic models allows inclusion of 
heterogeneity among gut microbiome and diet similar to human subjects, phenotype transfer to 
better understand cause-effect relationships, and complex reciprocal interactions among the host 
and microbiome. In terms of human studies, we need well controlled longitudinal studies 
incorporating functional genomic, transcriptomic, metagenomic, and metabolomic analyses as 
well as robust clinical metadata for the evaluation of “mechanism-based phenotypes.”. There are 
several factors that can affect the gut microbiome including diet, demographics, body mass 
index, medication etc. as described above and hence these should be controlled before linking the 
microbiome with host outcomes. In addition to understanding the role of microbiome in the 
pathophysiology of symptoms in FGIDs, assessing the impact of the microbiome on efficacy of 
dietary and pharmacologic therapy in conjunction with host features will allow for better 
treatment stratification compared to the current one size fits all approach. Finally, we need to 
move the needle from empirically selected prebiotic and probiotic therapies to the next 
generation of precise mechanism-based diagnostic and therapeutic interventions. The use of 
genetically engineered bacterial strains to assess the gut environment, release metabolites of 
interest at specific locations within the GI tract, and optimize drug metabolism appears to be on 
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the horizon190, 191. Rapid advances in these areas provide an optimistic outlook for microbiota-
based interventions in FGIDs.  
PERSPECTIVE 
It is now apparent that the gut microbiome is an integral player in the pathophysiology of 
FGIDs through its effects on host physiological processes even though the precise mechanisms 
underlying microbial regulation remain an area of active investigation. The improved 
understanding of factors that shape the gut microbiome allow us to better identify confounding 
effects in human studies, including physiological development through childhood and 
adolescence to adulthood30, 12811, and at the same time, appreciate the adaptation of this resilient 
microbial ecosystem to short- and long-term perturbations in host environment. A 
comprehensive view of the gut microbiome in both pediatric and adult FGIDs is important in 
order to account for the dynamics of the gut microbiome as it exhibits a continuum across the 
lifespan, with hallmark characteristics in different phases of life192. 
The expanding ecosystem of microbiome-based startups and industry funding, the shift 
away from compositional changes towards functional products of the microbiome, better 
integration of clinical metadata, and genetic engineering and synthetic biology tools to make 
designer probiotics targeting specific host functions, together instill confidence in our ability to 
move microbiome science from bench to the bedside.   
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Table 1: Microbial metabolites as mediators of gastrointestinal physiology 
*SCFA=short chain fatty acid; #5-HT=serotonin; Irritable bowel syndrome; $CDCA=chenodeoxycholic acid; ^DCA=deoxycholic acid 
Metabolite Microbial regulation Effect Mechanism 
*SCFA Fermentation of dietary 
starches to SCFA 
Motility Butyrate and acetate increase #5-HT biosynthesis193  
SCFAs provoke proximal colonic contractions via 5-HT in rats194 
  Sensation Butyrate increases colonic hypersensitivity in rats75, decreases visceral 
sensitivity in healthy humans76 
  Permeability Butyrate role in maintenance of intestinal barrier195 may vary depending on 
local concentrations, pH, and cellular differentiation 
  Immune activation SCFAs and n-butyrate regulate neutrophil function, increased tight junction 
protein expression, reduce cytokine and chemokine release196  
  Secretion SCFAs promote fluid and electrolyte absorption within the gut99 
Acetate effects both small intestine and colon through increased duodenal 
bicarbonate secretion100 and effects on colonic epithelial 5-HT3 receptor 
expression101 
Bile acids Deconjugation and 
dehydroxylation 
Motility $CDCA promotes propagating and non-propagating colonic contractions in 
humans197 
^DCA-induced intestinal peristalsis and contractions mediated by TGR555 
  Permeability Increased permeability associated with bile acids with two hydroxyl groups 
in α configuration198 
Bile acid receptor, TGR5, modulates intestinal barrier function in mice199 
  Secretion DCA and CDCA stimulate chloride and water secretion via inhibition of Cl-
/OH- exchange (Alrefai 2007) and activation of CFTR via cAMP98 
  Immune activation CDCA regulates intestinal antimicrobial environment in mice via Paneth 
cell α-defensins and C-type lectins200 
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Methane Gaseous by-product Motility Methane augments small bowel contractility and slows intestinal transit152 
Hydrogen sulfide Gaseous by-product Motility Sulfate-reducing bacteria slow intestinal transit in mice60 
Hydrogen gas Gaseous by-product Motility Hydrogen gas shortens transit in guinea pig colon62 
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Table 2: Summary of studies investigating pathophysiologic mechanisms and gut microbiota in patients with functional 
gastrointestinal disorders 
*IBS=Irritable bowel syndrome (IBS-D=diarrhea-predominant IBS, IBS-C=constipation-predominant IBS, PI-IBS=post-infectious IBS); 
&pcbo=Placebo; +HV=Healthy volunteer; **GBA=Gut brain axis; #HADS=Hospital Anxiety and Depression Scale; ∆SCFA=short chain 
fatty acid; @LFSD= Low fermentable substrate diet; ^scFOS= Short-chain fructooligosaccharide; δ FF3= urine trefoil factor 3; 
$SBI=Serum-derived bovine immunoglobulin/protein isolate; !LC-DG=Lactobacillus casei DG; ⌘LPS=lipopolysaccharide; 
∞BL=Bifidobacterium longum NCC3001 
Study Study 
population 
Intervention Sample Mechanism 
studied 
Role of microbiota 
Shin et al. 
2018201 
60 IBS*-D L. gasseri BNR17 
vs. pcbo& 
Fecal Transit Transit significantly ↑ during 8 weeks with L. 
gasseri BNR17  
Tap et al. 20177 110 IBS, 39 HV+ NA Fecal, 
mucosal 
Transit, GBA** ↑Transit with Clostridiales vs. Prevotella and 
Bacteroides enterotypes. No association 
between HADS# and enterotype 
Acosta et al. 
2016119 
24 non-
constipated IBS 
Rifaximin vs. 
pcbo 
Fecal Transit, 
permeability, 
SCFA∆ and bile 
acid production 
No significant effects of rifaximin on 
permeability, bile acids, SCFAs. Rifaximin 
associated with ↑ascending colon emptying, 
and colonic transit at 48H 
Dior et al. 2016202 15 HV, 15 IBS-C, 
16 IBS-D 
NA Fecal Fecal bile acids ↓bacterial deconjugation of bile acids in IBS-D 
and IBS-C feces vs. HV 
Le Neve et al. 
2016203 
100 IBS NA Fecal Sensation, 
transit 
Response to lactulose challenge associated 
with rectal sensitivity but not with fecal 
microbiota or transit  
Chumpitazi et al. 
2014131 
12 IBS children  LFSFD@ Fecal Transit, 
metabolite 
composition 
LFSD response associated with ↑abundance of 
Sporobacter and Subdoligranulum and 
↓Bacteroides, but not with transit. Stool 
metabolites (L-urobilin, cholate) associated with 
response and microbiome composition 
Jeffery et al. 
2012156  
37 IBS, 20 HV NA Fecal Sensation, 
transit, GBA 
Proteobacteria associated with ↑mental 
component and pain threshold; Actinomycetales 
inversely associated with depression. 
Desulfohalobiaceae and Methanobacteriaceae 
associated with transit 
Labus et al. 
2017204  
29 IBS, 23 HV NA Fecal GBA No correlations between anxiety or depression 
symptom scores and microbial parameters; 
Clostridia and Bacteroidia correlated with 
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sensory integration regions 
Liu et al. 2016205 40 IBS, 15 
Depression, 25 
IBS and 
Depression, 20 
HV 
NA Fecal GBA, immune ↑Bacteroidetes and ↓Firmicutes in IBS-D, 
depression, and IBS-D with depression; Colonic 
mucosa inflammation associated with 
↑Bacteroides or Prevotella 
Azpiroz et al. 
2017206 
79 IBS scFOS^ vs. pcbo Fecal GBA, sensation  scFOS reduced anxiety scores and increased 
fecal Bifidobacteria; No significant difference in 
rectal sensory threshold foe scFOS vs. pcbo 
Le Gall et al. 
2011207  
10 IBS, 13 UC, 
22 HV 
NA Fecal Fecal 
metabolites 
Correlation between gut microbiota profile and 
metabolite composition 
Heitkemper et al. 
2018208 
93 IBS NA Fecal Permeability Higher stool δTFF3 associated with lower 
permeability and microbial diversity.  
Christensenellaceae inversely related to stool 
TFF3. 
Bednarska et al. 
2017209 
32 IBS, 15 HV NA Mucosal Immune, 
Permeability 
Increased permeability to E. coli strain HS and 
S. typhimurium in IBS biopsies vs. controls; 
↑plasma VIP in IBS vs. HV; ↑tryptase and 
mast cells in IBS biopsies vs. HV 
Valentin et al. 
2017210 
15 IBS-D SBI$ Duodenal 
brushing, 
fecal 
Immune, 
permeability, 
metabolism 
Bile acid synthesis, tryptophan metabolism, 
permeability and stool microbiome not 
significantly different with SBI. Changes in β 
diversity analysis, increased ↑Proteobacteria 
Burkholderiales, Firmicutes Catonella, and 
unclassified genus organisms with SBI in 
duodenal microbiome. 
Ko  et al. 2013211 53 IBS-D Herbal (GJS), 
Probiotic 
(Duolac7S), pcbo 
Fecal Permeability  GJS with DuoLac7 ↑B. lactis, L. rhamnosus, L. 
plantarum. No significant difference observed in 
permeability 
Crouzet et al. 
201366 
3 IBS-C, 2 HV NA Fecal Rectal 
sensitivity 
IBS with rectal hypersensitivity have 
↓bifidobacteria, ↑Enterobacteriaceae, and 
↑H2-utilizing sulfide-producing bacteria vs. HV 
Shulman et al. 
2017136 
103 IBS children Fiber vs. placebo Fecal GBA, 
permeability 
No differences in psychological symptoms, 
permeability, or microbiome between groups 
Compare et al. 
2017212 
10 IBS-D, 10 HV 
(ex vivo) 
LC-DG!, 
postbiotic 
Mucosal Immune  ↑IL-1α, IL-6 and IL-8 mRNA, TLR-4 protein 
expression with ↓IL-10 mRNA levels in PI-IBS 
D vs. HV. LC-DG and PB ↓mRNA levels of pro-
inflammatory cytokines and TLR-4 but ↑IL-10 
after LPS⌘ stimulation 
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Hustoft et al. 
2017213 
20 IBS-D or IBS-
M 
low FODMAP 
diet, FOS vs. 
pcbo 
Fecal Immune, SCFA ↓IL-6 and IL-8, fecal bacteria (Actinobacteria, 
Bifidobacterium, Faecalibacterium prausnitzii), 
total SCFAs, and n-butyric acid on LFD. FOS 
supplement then ↑levels of these bacteria, but 
cytokines and SCFAs unchanged. 
McIntosh et al. 
2017214 
37 IBS low vs. high 
FODMAP 
Fecal Urinary 
metabolites 
Significant correlations between relative 
bacterial abundance and symptoms and urinary 
metabolites (histamine, p-hydroxybenzoic acid) 
Sundin et al. 
2015215 
11 PI-IBS, 10 HV 
(ex vivo) 
NA Mucosal Immune 
 IL-1β ↑ in PI-IBS vs. HV after stimulation with 
Subdoligranulum variabile; IL-10 ↓ in HV vs. PI-
IBS after stimulation with Eubacterium limosum. 
Sundin et al. 
2015216 
13 PI-IBS, 19 
IBS, 16 HV 
NA Fecal, 
mucosal 
Immune, GBA Naive CD8+ CD45RA+ intraepithelial 
lymphocytes and lamina propria lymphocytes 
negatively correlated with mucosal microbial 
diversity. Fecal microbial diversity negatively 
correlated with HADS 
Pinto-Sanchez et 
al. 2017127 
44 IBS BL∞ vs. pcbo Fecal  GBA, immune, 
urinary 
metabolites, 
neurotransmitte
rs, and 
neurotrophins. 
BL ↓depression and associated with ↓limbic 
reactivity. No difference in fecal microbiota, 
serum markers of inflammation, neurotrophins 
and neurotransmitters. Reduced urine 
methylamines and aromatic amino acids 
metabolites with BL. 
Parthasarathy et 
al. 2017217 
25 CC, 25 HV NA Fecal Transit Reproducibility of fecal microbiota lower in 
normal transit vs. slow transit constipation 
Parthasarathey et 
al. 2016157 
25 CC, 25 HV NA Fecal, 
mucosal 
Transit Fecal microbiota profile associated with colonic 
transit; genera from Firmicutes correlated with 
faster colonic transit.  
Tian et al. 
2017218  
60 STC Fecal microbiota 
transplantation 
(FMT) 
NA Transit FMT associated with faster transit vs. control 
treatment 
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Figure Legends: 
Figure 1: Factors that shape the gut microbiota 
Figure 2: Distribution of the gut microbiota within the gastrointestinal tract along its 
longitudinal and radial axes 
Figure 3: Gut microbiota effects on host physiology including gastrointestinal motility, 
sensation, secretion, epithelial barrier integrity, immune activation, and brain-gut communication 
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